TOPIC
 / company

Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals: A leading Chinese pharmaceutical company, headquartered in Lianyungang, Jiangsu, with corporate offices in Shanghai and a global presence including R&D centres in the US and Europe. It specialises in the research, development, manufacturing, and distribution of innovative drugs, primarily focusing on oncology, surgical medicines, cardiovascular, and metabolic diseases. The company is recognised as China’s largest listed pharmaceutical firm and consistently ranks among the top global pharmaceutical companies. Its overall business focus is on innovation, significant R&D investment, and global expansion to address unmet medical needs.
China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

China stock market

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

videocam
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

10
Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Hengrui gets boost from fifth drug-licensing deal of year

Shares rise after Mumbai-based Glenmark Pharmaceuticals strikes deal for cancer drug.

Health in China

Beijing tackles drug price wars with new tendering rules in anti-involution push

China’s new drug procurement rules prioritise quality over price in a bid to curb cutthroat competition.

Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

China’s weight-loss drugs market could grow to US$5.6 billion in 2035, according to Goldman Sachs. Photo: Shutterstock
Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Shares of WuXi Biologics have more than doubled year to date. Photo: Shutterstock
IPO

Zijin Gold’s Hong Kong IPO draws GIC, Millennium and Hillhouse, sources say

The company could raise more than US$3 billion and could start taking orders from other investors and the public as soon as Friday.

Banking & finance

China’s healthcare segment eyes record fundraising amid global investor surge

China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.

IPO

Hong Kong IPO pipeline swells as Chinese tech listings lure global investors

More than 200 companies await approval amid ‘strong global interest in China’s tech sector’, CEO of bourse operator says.

Hong Kong Exchanges and Clearing CEO Bonnie Chan Yiting speaks the the bourse operator’s Future Tech Summit on September 5, 2025 in Hong Kong. Photo: Handout
Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

The headquarters of Jiangsu Hengrui Pharmaceutical in Lianyungang Economic and Technological Development Zone, in Jiangsu province. Photo: Costfoto/Future Publishing via Getty Images
China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

videocam
Biomedicine: Companies

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits

Novel drug roll-outs and revenue from licensing buoy results.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Opinion | Biotech successes helping Chinese intellectual property go global

After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own innovations.

videocam
Visitors walk beside the booth of British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca during the third China International Supply Chain Expo in Beijing on July 17. Photo: EPA
Wealth management

Shareholders of Chinese firms eye Hong Kong for family offices: asset manager

Chairman of Oakwise Capital says wealthy mainland Chinese will continue looking to Hong Kong as a home for their family offices.

Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement